Contact
Please use this form to send email to PR contact of this press release:
Strong Year-End Results, Stock Dividend Approval, and Share Structure Reduction to Counter Short Selling: (Nasdaq: NRXP)
TO:
Matthew Duffy, Chief Business Officer
NRx Pharmaceuticals, Inc.
+1 484-254-6134